glp-1 depression UF researchers demonstrate GLP-1RAs' potential to treat Association between GLP-1 receptor agonist

The participants were divided into the following experimental groups or a placebo group: 1 mg of retatrutide (subcutaneously) 4 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 4 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 12 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg Here are the detailed results of the trial at 24 weeks and 48 weeks: Phase II clinical trial projects promising results of retatrutide in weight management

Fatigue or lethargy: A minority of users experience tiredness, sometimes related to altered sleep patterns during the adjustment period

These powerful therapy choices have been established and completely checked in animal versions

Treatment frequency is typically 13 sessions per week, with the total number of treatments individualized based on health status, goals, and provider guidance

However, the researchers the trial was marked as completed, but in 2016 they cancelled submission of the results never published the results This is a red flag: we dont know if an issue or toxicity was discovered, or if it was simply a business decision

The most common include nausea, vomiting, constipation, diarrhea, abdominal pain, and malnutrition